CIK细胞在肝癌治疗中的研究进展.docVIP

CIK细胞在肝癌治疗中的研究进展 龚建平 摘要：肝细胞癌是肝脏肿瘤中最常见的组织学第常见的，严重人类的健康。、肝动脉化疗栓塞TACE）射频消融（RFA）肝细胞癌的。复发率较高，长期生存率仍。免疫细胞在肿瘤治疗上巨大潜力，过继免疫治疗已成为研究方向。诱导的杀伤细胞cytokine induced killer cells, CIK）肿瘤免疫治疗上的特征。介绍该细胞的基本特征并其在治疗中的。 过继免疫治疗CIK细胞；肝细胞癌 ____________________________________________________ 1重庆云阳县医院外科 邮编：404500 2重庆医科大学附属第二医院肝胆外科 400010 第一作者：谭智勇,电话：@ 通迅作者：龚建平，电话Email:gongjianping11@126.com Research Advances on CIK cells’ clinical therapy in liver cancer Abstract: Hepatocellular carcinoma (HCC) is the most common histological type of liver cancer and the third most common cause of malignancy worldwide. Surgery, transcatheter arterial chemoembolization (transcatheter arterial chemoembolization, TACE) and radiofrequency ablation (radiofrequency ablation, RFA) are considered as the main treatments for HCC today. However, the recurrence rate is still high, and long-term survival is unsatisfactory. Due to the huge potential demonstrated by immune cells in treating malignant tumors, adoptive immunotherapy has become an important research direction in recent years. Cytokine induced killer cells (CIK) are raising concerns because of their unique features in tumor immunotherapy. This paper is aimed to introduce the basic characteristics of CIK cells and summarize research progresses on CIK cells’ clinical therapy in liver cancer. Key words：Adoptive immunotherapy; Cytokine induced killer cells; Hepatocellular carcinoma 肝细胞癌（Hepatocellular carcinoma, HCC) 恶性度高，[1]。肝移植，目前、肝动脉化疗栓塞transcatheter arterial chemoembolization, TACE）射频消融（radiofrequency ablationRFA）的[2]。手术技术以及诊断方法相比以前有了很大进步，但是固有免疫及特异性免疫低下，切除不彻底及其对放化疗毒副作用相关因素，肝癌的复发肝外转移率较高，长期生存率仍%的病人在确诊后一年内死亡。在肝癌治疗中一种来传统治疗手段的疗效尤其重要。 在肿瘤巨大潜力，肿瘤综合治疗的第四种模式受到重视。[3-6]，已有多种免疫细胞如（dentritic cells, DC）T淋巴细胞（cytotoxic T lymphocytes, CTL）（natural killer cells, NK）（lymphokine-activated killer cells, LAK）肿瘤的研究临床应用中展现了的效果。上述细胞相比，强大的抗肿瘤活性非杀伤肿瘤细胞功能且其率，使成为了免疫治疗的。 1CIK细胞的来源 Schmidt-Wolf[7]于1991年首次报道了CIK细胞。CIK细胞定义为通过体内获得的单个核细胞（peripheral blood monocytes, PBMC）多种细胞因子共同